AFFILOGIC | Relocating its production capabilities
Winner of the French Resilience Call for Proposals in late 2020, Affilogic, a cluster member specialising in the discovery and... View Article
New member | Apo Tech Care
Apo Tech Care’s mission is to be the facilitator in implementing a real care 4.0 (participative, personalized, preventive and predictive),... View Article
France Relance | GoLiver Therapeutics awarded a grant of 1 M€ to produce regenerative cells
The aim of this project is to manufacture, in France, a cell therapy product from pluripotent stem cells for the... View Article
Valneva Joins Euronext SBF 120 and CAC Mid 60 Indices
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
New member | Althenas
Althenas supports AI & health projects of public and private organizations, from consulting advice to complete project management. The company... View Article
OSE Immunotherapeutics and ARCAGY – GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp... View Article
New member | Orthopus
ORTHOPUS designs open-source technical aids for physical disabilities at fair prices. Based in Nantes, this company develops two ranges of... View Article
Valneva and Pfizer announce initiation of phase 2 study for Lyme disease vaccine candidate
The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine... View Article
The European Patent Office has granted McSAF a patent for DAR 4 antibody-drug conjugates technology
The European Patent Office (EPO) has granted the patent number EP3521314 on the McSAF Inside® technology to access DAR 4... View Article
Valneva initiates phase 3 clinical lot consistency study for its single-shot chikungunya vaccine candidate
Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced that... View Article